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Background. Antigenic characterization of inﬂuenza viruses is typically based on hemagglutination inhibition
(HI) assay data for viral isolates tested against strain-speciﬁc postinfection ferret antisera. Here, similar virus char-
acterizations were performed using serological data from humans with primary inﬂuenza A(H3N2) infection.
Methods. We screened sera collected between 1995 and 2011 from children between 9 and 24 months of age for
inﬂuenza virus antibodies, performedHI tests for the positive sera against 23 inﬂuenza viruses isolated between 1989 and
2011, and measured HI titers of antisera against inﬂuenza A(H3N2) from 24 ferrets against the same panel of viruses.
Results. Of the 17 positive human sera, 6 had a high response, showing HI patterns that would be expected from
primary infection antisera, while 11 sera had lower, more dispersed patterns of reactivity that are not easily explained.
The antigenic map based on the high-response human HI data was similar to the map created using ferret data.
Conclusions. Although the overall structure of the ferret and human antigenic maps is similar, local differences in
virus positions indicate that the human and ferret immune system might see antigenic properties of viruses differently.
Further studies are needed to establish the degree of similarity between serological patterns in ferret and human data.
Keywords. primary infection; inﬂuenza; human antisera; antigenic cartography; antibody landscapes.
Inﬂuenza viruses are notorious for their continuous an-
tigenic evolution and resulting ability to escape prior
immunity and reinfect previously exposed hosts [1, 2].
To protect against inﬂuenza virus infection, an effective
vaccine is available, but to maintain vaccine effective-
ness, the antigenic properties of circulating viruses need
to be known, and the vaccine strains have to be updated
when appropriate to avoid antigenic mismatch [3, 4].
To this end, the World Health Organization (WHO)
coordinates a global inﬂuenza surveillance network
that routinely characterizes the antigenic properties of
isolated viruses, using the hemagglutination inhibition
(HI) assay [5]. For antigenic characterization, sera
from a panel of ferrets that were each experimentally
infected with a different virus strain are used. The re-
sulting HI tables contain serum antibody titers with
patterns that are now fairly readily interpretable and
understood, because antigenic differences among virus
strains can be mapped with antigenic cartography [1].
An antigenic map quantiﬁes and displays antigenic dif-
ferences as distances between viruses, such that similar
viruses cluster closely on the map, whereas viruses that
are antigenically different are found further away. This
method is now routinely used to assist the vaccine strain
selection process and surveillance activities of theWHO
and is based on large HI tables of inﬂuenza virus iso-
lates that were titrated against a panel of ferret sera.
Although human sera are used in the vaccine strain se-
lection process for activities such as evaluating the re-
sponse to vaccines in vaccine trials, their analysis is too
complicated for trivial use in the antigenic characterization
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of inﬂuenza viruses. For example, when a human has had 2
separate exposures to inﬂuenza virus, titers to both infecting vi-
ruses will be increased, which may potentially be interpreted in-
correctly as an antigenic similarity between the 2 different
infecting viruses. A recent solution to the interpretation of
human serological data is the generation of an antibody land-
scape, which expands an antigenic map in another dimension
by displaying the HI titers measured for the human serum for
each virus [6].
In addition to the fact that human data are typically represen-
tative of multiple exposures, there are manifold other reasons,
often involving factors associated with experimental control,
why ferret data are preferred for the antigenic characterization
of virus isolates: the exact infecting virus strain for a ferret is al-
ways known, whereas for human infections this is much less
common; ferret serum samples can be obtained at a standard-
ized time point after infection, when there is a peak in antibody
titers, increasing the sensitivity of interpretations of the result-
ing HI tables; sufﬁciently large serum volumes for extensive and
repeated testing are available; and sera can be newly generated
against viruses that circulated in the past.
The traditional interpretation of ferret HI data when per-
forming antigenic characterization, the WHO vaccine strain se-
lection process, and the expansion of a ferret-based antigenic
map into an antibody landscape all implicitly assume that anti-
genic characteristics are similar to what would be measured in a
human, when using the ferret animal model. Interestingly, a
small comparison of titers from swine sera and ferret sera
gave similar results for swine inﬂuenza A(H3N2) strains [7],
and results of antigenic characterization of avian inﬂuenza A
(H5N1) isolates with ferret sera were consistent with titer pat-
terns in HI tests with avian antisera [8, 9]. Similarly, it is impor-
tant to carefully compare and know the antigenic properties of
human viruses in relation to the human immune system and
antibody response. To our knowledge, validation studies to con-
ﬁrm the use of the ferret as a model system for the antigenic
characterization of seasonal inﬂuenza virus isolates in the
context of different human immune responses have not been
performed. This is understandable, because it is challenging
to obtain human sera that fulﬁll the stringent requirements of
having been collected after the individual’s ﬁrst inﬂuenza
virus infection and during the circulation of different antigenic
clusters.
This study presents the ﬁrst human antigenic map made for
inﬂuenza viruses and is based on a data set of historical and re-
cent serum samples, to enable antigenic characterization of var-
ious inﬂuenza A(H3N2) isolates recognized by human antibody
repertoires. By having access not only to recent but also to his-
torical serum samples from children, we were not limited to the
characterization of a small subset of recently circulating viruses.
Instead, we investigated serum responses against viruses isolat-
ed over 22 years of inﬂuenza A(H3N2) evolution, across 9
antigenic clusters. These data enable a comparison of antigenic
properties of viruses deﬁned by human sera after natural infec-
tion to those deﬁned by ferret sera obtained after experimental
infection.
METHODS
Human serum samples were selected from the serum bank of
the Department of Viroscience at the Erasmus Medical Center
(Rotterdam, the Netherlands). Only sera from patients seen at
the Sophia Hospital Pediatrics ward who, and of whom the
caregivers, did not object to scientiﬁc use of excess material
were included in this study. The study protocol was reviewed
and approved by the medical ethics board of the Erasmus Uni-
versity Medical Center (study number MEC-2012-181). In-
formed consent was waived because patient inclusion was
performed retrospectively and data handled anonymously.
From the 5129 individuals, we selected individuals aged 270–
729 days, to minimize interference from transplacentally
acquired maternal immunoglobulin G antibodies (immuno-
globulin A antibodies in breast milk were not considered rele-
vant for our studies of sera) and multiple seasonal inﬂuenza
virus infections [10, 11]. We excluded sera from patients in
whom the possibility of nonnaturally obtained antibody re-
sponse existed, and samples from patients with immune deﬁ-
ciencies were also excluded. Based on surveillance data of the
incidence of inﬂuenza A(H3N2) infection in the Netherlands,
we selected samples that were collected within 2 weeks either
side of the epidemic season window. We then selected samples
with at least 150 µL of serum, leading to a ﬁnal sample set of 72
sera (Supplementary Methods).
HI assays were used to screen the serum samples for inﬂuen-
za virus–speciﬁc antibodies against the vaccine strain for the an-
tigenic cluster that circulated in that season (Supplementary
Data Set 1), using the standard protocol [12, 13]. The 17 inﬂu-
enza virus–positive samples were subsequently tested further
with the HI assay against a panel of 23 viruses (Supplementary
Data Set 2). Supplementary Table 1 lists the frequencies for the
various reasons for hospitalization and diagnostic testing of
these 17 patients, of whom 4 had underlying medical conditions
(congenital kidney disease, bone formation disorder, neonatal
cataract, and recurrent wheezing). For comparative purposes,
we tested the sera of 24 ferrets against the same panel of viruses
with the HI assay. Supplementary Data Sets 3–7 show the HI
results and subsets used for antigenic cartography (Supplemen-
tary Methods).
Antigenic maps were used to infer antigenic differences
among virus strains, with each titer in the HI table specifying
a target distance for the virus and serum points in the antigenic
map [1].
Antibody landscapes were constructed as described by Fon-
ville et al [6], except for a modiﬁcation to model the effects of
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the x and y antigenic coordinate variables independently (Sup-
plementary Methods).
RESULTS
We selected sera from a biobank of stored blood specimens col-
lected from children between the ages of 9 and 24months for any
viral diagnostic analysis between 1995 and 2012. Upon screening
the 72 selected sera against inﬂuenza virus–speciﬁc antibodies
with the HI assay, 17 (23.6%) had an HI titer of ≥10 against
the screening virus. Interestingly, there was a dichotomy in the
HI screening titers, with one group of relatively high-responding
individuals (6 [8.3%]; HI titer range against screening virus, 240–
3840), and a group of low responders (11; HI titer range against
screening virus, 10–60; Supplementary Data Set 2).
The 17 inﬂuenza virus–positive human sera and 24 ferret sera
were subsequently titrated with HI against a panel of viruses.
Figure 1 shows the resulting HI titer patterns, with viruses
color-coded by antigenic cluster, as determined from previously
published antigenic maps based on ferret sera [1, 6]. Evolution of
inﬂuenza A(H3N2) virus since its introduction in humans in
1968 has included the addition of glycosylation sites [14, 15]. Al-
though the shielding of epitopes by glycans has been reported fre-
quently to alter or prevent the ability of neutralizing antibodies to
bind the virus by masking or modifying antigenic sites [16, 17],
we do not see signiﬁcant changes in the number of antigenic
clusters recognized by sera over time, in line with the lack of
synchronicity between antigenic cluster transitions and changes
in glycosylation [18].
Figure 1 highlights how titers between sera and viruses that
are many years apart (long-distance titers) are more common
for the human sera than for the ferret sera: for example, sera ob-
tained after primary infection from the 3 low responders in the
1994–1995 season (S95-2, S95-3, and S95-4) had titers to strains
isolated in 2011, whereas such patterns were uncommon in the
ferret data. Similarly, S10-2 and S11-1 had titers to strains that
circulated around 2 decades before the child was born. Al-
though some serum-virus combinations in the ferret data had
titers when they would not be expected, this is a more common
feature in the human data, particularly in the sera of low re-
sponders. In general, the ferret sera appear to show stronger
and narrower patterns of reactivity than the human sera.
We proceeded by focusing our analyses on the sera of the
high responders and generated an antigenic map based on
sera from the following 6 individuals: S95-1, S00-1, S00-2,
S04-1, S04-2, and S04-3 (Supplementary Data Set 4). The num-
ber of viruses per antigenic cluster can vary and still result in
robust antigenic maps, as long as the density of viruses is high
enough. Viruses can be placed reliably on a map once there are
numeric titers (ie, titers that are not <10) against at least 2 sera,
and we mapped the eligible 14 viruses, isolated between 1992
and 2011. Figure 2 displays the resulting antigenic map, with
viruses colored by antigenic cluster and antisera colored by
the antigenic cluster that was present in the season the sample
was obtained. Interestingly, the viruses mostly still clustered by
color; that is, the assignment to antigenic clusters based on fer-
ret sera reactivity matches fairly well with the human antigenic
map. The antigenic map represents the measured HI data well,
as characterized by small error lines (Supplementary Figure 1).
Figure 1. The measured hemagglutination inhibition (HI) titer with an
increasing symbol size (<10 are size 0) for the ferret sera (top) and
human sera (bottom), sorted by the year of isolation of the infecting
virus and the year of serum collection, respectively, against the viruses
sorted by their antigenic cluster. Different antigenic clusters are indicated
with different colors, as follows: blue, Sichuan-87 cluster; red, Beijing-89
cluster; pink, Beijing-92 cluster; dark green, Wuhan-95 cluster; light blue,
Sydney-97 cluster; yellow, Fuijan-02 cluster; light green, California-04 clus-
ter; orange, Brisbane-07 cluster; and purple, Perth-09 cluster. See also
Supplementary Data Sets 2 and 3.
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The human sera were relatively close to the viruses for the
corresponding antigenic cluster, with the possible exceptions
of sera S04-1 and S04-2. S04-1 may have been infected before
the 2003–2004 season, in the 2001–2002 season (although
high levels of maternal antibodies would be expected for an in-
dividual this soon after birth), or in the 2002–2003 season,
when the relatively small inﬂuenza epidemic in the Netherlands
was dominated by strains that were antigenically like the
Sydney-97 antigenic cluster [19]. An infection with a Sydney-
97–like virus would explain the location of this serum in the an-
tigenic map close to such isolates. The S04-2 serum was anti-
genically slightly more advanced than the surveillance data for
the 2003–2004 inﬂuenza season in the Netherlands [20] and
similar to the California-04–like viruses that circulated during
the 2004–2005 epidemic [21]. Supplementary Figure 2 shows a
similar antigenic map of the children’s HI data, made with a col-
umn basis of at least 1280 (which is conventionally used for the
analysis of ferret serology), and underlines how the antigenic re-
lationships and positions of the sera were similar for both
analyses.
Importantly, we can compare the positioning of the viruses
on the antigenic map as deﬁned by the human sera with an
antigenic map based on ferret sera. Figure 3A shows an antigen-
ic map of 21 ferret sera (Supplementary Data Set 5) measured
against the same subset of viruses, and Figure 3B displays pro-
crustes arrows, in which the arrowhead indicates the correspond-
ing positions of the viruses in the human map. Although the
overall structure of the 2 maps remained similar in terms of the
relative ordering of antigenic properties (eg, the Beijing-1992 and
Wuhan-1995 clusters are closer to each other than to the Califor-
nia-2004 cluster), there are visible differences between the 2
maps. Additionally, the overall spread of the antigenic map com-
prises fewer antigenic units when based on human sera than
when based on ferret sera. Similar observations were made
when comparing the human and ferret maps made with the min-
imum column basis requirement (Supplementary Figure 3) and
when making the ferret map based on a subset of 6 sera only
(Supplementary Figure 4).
Subsequently, we explored how the human antigenic map
would change when 2 of the low responders were included
(these sera had at least 1 titer of at least 240, instead of a screen-
ing titer of at least 240; Supplementary Data Set 6). The result-
ing map, shown in Figure 4A, is quite comparable to the
antigenic map made without these 2 sera: the procrustes arrows
in Figure 4B are relatively small, with the exception of a large
change in the position of virus VI/361/11. The new addition
of viruses VI/1/89 and PE/16/09 caused the appearance of the
map to become circular, as a result of some long-distance cross-
reactivity of some of the recent sera against VI/1/89, pulling this
virus inward. The ferret map made with the same subset of vi-
ruses (Figure 4C and Supplementary Data Set 7) also has a
moderately circular appearance but is spaced more widely, com-
pared with the human map (see the procrustes arrows in Fig-
ure 4D). In general, broader reactivity will typically result in
antigenic maps becoming more circular than linear.
To visualize the titer pattern of an individual’s serum, we
added an extra dimension to the antigenic map to display the
measured HI titers. By plotting a smooth surface through
these titers, an antibody landscape is created, which plots the
antibody recognition patterns as a function of the antigenic re-
lationships among viruses [6]. Figure 5 displays the antibody
landscapes of the 6 sera from the high responders, in which
each landscape represents an individual’s antibody proﬁle, with
elevations corresponding to regions in the antigenic map with
higher antibody levels and depressions corresponding to regions
Figure 2. Antigenic map based on the hemagglutination inhibition (HI)
titers of the sera of the 6 high responders and representative virus isolates
of different antigenic clusters [1]. In an antigenic map, both vertical and
horizontal axes represent antigenic distance. The spacing between grid
lines is 1 antigenic unit distance, corresponding to a 2-fold dilution in
the HI assay (eg, 2 units correspond to a 4-fold dilution, and 3 units cor-
respond to an 8-fold dilution). Different antigenic clusters are indicated
with different colors as in Figure 1. Sera are shown with a gray outline,
and serum names indicate the season of serum collection (eg, specimen
S95-1 was collected in 1994–1995). The size and shape of each symbol
reflects the certainty in positioning of the virus or serum and represents
the coordination confidence area as locations on the map that the point
could also occupy without increasing the stress of the map with >0.5.
The shape size typically increases as fewer HI titers are available. This
map was made without a minimum column basis.
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with lower antibody reactivity. These antibody landscapes are
the ﬁrst ones made for human sera collected after primary in-
fection and the ﬁrst ones made on a human-serum based anti-
genic map. When comparing the antibody landscapes of the
human sera with the landscapes of the most similar ferret
sera, the landscape shapes are remarkably similar (Supplemen-
tary Figure 5).
DISCUSSION
This study evaluated the HI titer patterns of 17 sera from chil-
dren between 9 and 24 months of age. HI titers after primary
infection in the literature vary widely and are known to be de-
pendent on the interval between infection and serum collection
[22–26] but also possibly on the virus subtype [22, 27] and the
age of the individual [28, 29]. Some studies in the literature fol-
low individuals from birth [24, 30] and hence have certainty
about an infection being a primary exposure, while other rele-
vant studies report titers for age groups that are typically asso-
ciated with ﬁrst infection [10, 22, 28, 31–35].
In the 2 studies that reported titers after primary infection
with inﬂuenza A(H3N2), Wright et al observed a geometric
mean titer (GMT) of 271 among 8 children between 6 and 23
months old [22], and Burlington et al found a GMT of 147
among 10 children between 1 and 4 years of age who were fol-
lowed from birth [30]. In the Pienter study [10], children aged
12–24 months had a GMT against inﬂuenza A(H3N2) of 329.
These values are in line with the high titers we ﬁnd in the sera of
high-responders.
The reason for the titer patterns observed in the low-
responding individuals remains unclear. Although the timing
of the sample collection in relation to any inﬂuenza virus infec-
tion is unknown and will vary from person to person, there was
no difference between the low-responder and high-responder
groups with respect to the time of sample collection in relation
to the dates of that season’s epidemic. The sera from the low re-
sponders did not have the same reactivity patterns as specimens
from the high responders at lower HI values but instead showed
more-dispersed reactivity patterns. Subclinical infection or an-
tigen exposure, which would potentially lead to lower HI titers
Figure 3. Comparison of antigenic maps based on ferret and human sera. A, Antigenic map based on 21 ferret sera, with the same virus set as in Figure 2
(made without minimum column basis). Sera are shown in gray. B, Procrustes arrows from each virus point to its corresponding position in the human map in
Figure 2.
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[36], do not explain these odd reactivity patterns. Sometimes
these titers extended to antigenic clusters that circulated long
before the child was born or to future antigenic clusters that
circulated many years after collection of the serum specimen.
Maternal antibodies might be able to explain the former but
not the latter observation. Moreover, we had a fairly conservative
selection criterion (age, >9 months) to avoid detection of mater-
nal antibodies asmuch as possible, and the age rangeswere similar
in the low-responder and high-responder groups. The dispersed
reactivity patterns could possibly be the result of the existence of
natural antibodies. Alternatively, these patterns might also arise
through cross-reactivity with antibodies induced after infections
Figure 4. Addition of 2 additional sera to the human antigenic map. A, Antigenic map of sera from the 6 high responders plus 2 additional sera with titers
of at least 240. B, Procrustes arrows displaying for each virus and serum in panel A its corresponding position in Figure 2. C, Antigenic map of ferret data,
using the same virus set as in panel A. D, Procrustes arrows showing the position of each virus in the ferret antigenic map shown in panel C in the human
antigenic map shown in panel A.
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with other pathogens, such as other inﬂuenza viruses or even
pathogens other than inﬂuenza virus, which is likely in children
of this age group but not in speciﬁc-pathogen-free ferrets. Further
studies are necessary to investigate the cause of the patterns seen
in the low responders and will require the collection of a larger
serum volume for testing.
We have, for the ﬁrst time, constructed an antigenic map of
inﬂuenza viruses based on human antibody recognition data.
This antigenic map was based on an extensive set of human
HI titers, spanning both a long interval of serum sampling
and comprising 2 decades of evolution in the inﬂuenza virus
test strains. Our data, and in particular the antibody landscapes,
also illustrate the antibody response in terms of strength and
breadth among children after their ﬁrst infection and across a
range of different infecting strains and seasons. It would be
very interesting to study how this response changes as an indi-
vidual experiences their second and third infection, to investi-
gate how the antibody landscape of an individual is built up
over time [6]. Indeed, in the context of vaccine strain selection,
a previous exposure history might alter the antibody landscape
and thus the immune response in a such way that data from an-
tigenic maps based on antisera obtained after primary infection
may not provide the best possible protection against inﬂuenza
viruses for nonnaive individuals [6, 37, 38].
The human antigenic map was based on 6 high-responding
human sera and is therefore by deﬁnition less robust than the
ferret map based on 21 ferret sera. For example, the larger sym-
bol sizes in Figure 2 for the more-recently isolated viruses indi-
cate relatively larger uncertainty in the positioning of these
viruses and are a natural result of fewer and lower numeric titers
against those strains, because the sera were only from older in-
ﬂuenza seasons. When including more-recently collected sera,
as in Figure 4, the uncertainty in the positioning of the more
recent viruses therefore decreased. However, even when making
a map based on 6 ferret sera only (Supplementary Figure 4), the
ferret map spanned a larger antigenic range than the human an-
tigenic map. This may be because inoculation protocols and
serum collection for ferrets have been optimized to yield high
titers.
The human sera obtained after primary infection were simi-
lar but not identical to the ferret sera, which were obtained
under controlled conditions. For example, the time of sample
collection of ferret sera was standardized at 2 weeks after infec-
tion, whereas the time between infection and sample collection
is unknown for the human sera. We tried to minimize variation
in the times after infection at which the human sera were col-
lected by only selecting samples obtained during a narrow win-
dow around the epidemic in the Netherlands for each season,
but our ﬁndings are still limited by the absence of information
on infection history. Additionally, whereas the infecting strain
was known for ferret sera, this information was not available
for the human sera, and some children may have been infected
in a season preceding the season during which the serum was
drawn. Another potential difference between the ferret and
children sera is that the route and dose of infection were stan-
dardized and known for the ferrets but might have varied for
the children; similarly, the ferrets were infected with laborato-
ry-passaged viruses, whereas the children were exposed to un-
passaged circulating virus. Finally, the immunological maturity
between the young adult ferrets and the 9–24-month-old
children might have been different.
Despite these differences between the experimentally ob-
tained ferret sera and human sera obtained under less-
controlled conditions, the ferret and human maps are globally
Figure 5. Antibody landscapes [6] of the 6 high-responding human sera using the human antigenic map of Figure 2. Antibody titers of serum specimens
(gray dots) are displayed along the z-axis, with higher titers and higher regions of the antibody landscape corresponding to high antibody levels in an
individual.
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similar, indicating that the ferret sera are able to detect useful
information on overall antigenic differences among virus strains.
However, the narrower spacing of the human map as compared
to the ferret antigenic map, as well as the differences in the local
positioning of the viruses between the maps, may be relevant.
Therefore, a carefully planned prospective experiment in
which a larger number of human sera are obtained at known
times after infection is warranted to further test these differenc-
es. The germ-line B-cell receptor repertoires may be different
between humans and ferrets, which would lead to different an-
tibody mixtures. If the human and ferret antibodies respond to
different epitopes on the hemagglutinin, antigenic maps would
be different as a result. In case the different positioning is truly
caused by differences in how antigenic properties are detected
by ferret versus human immune systems and is relevant to vac-
cine strain selection, it might be helpful to supplement the ferret
data with data on human sera obtained after primary infection.
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